Nureca Receives Approval for Manufacturing Facility in Punjab

Nureca Limited has received formal approval from the Department of Industries & Commerce, Government of Punjab (Invest Punjab), to set up a new manufacturing facility in Village Sundra, Sub-Tehsil Zirakpur, District SAS Nagar, Punjab. The approval has been granted under the Industrial and Business Development Policy (IBDP) – 2022.

Manufacturing Focus

The new unit will focus on the production of health and wellness equipment. This addition is expected to contribute to Nureca’s existing domestic manufacturing infrastructure. The company currently operates in segments such as chronic device care, orthopaedics, mother and child products, nutrition supplements, and wellness essentials.

Nureca’s registered office is located in Goregaon East, Mumbai, while its correspondence office is based in Chandigarh.

Policy Benefits

Under the IBDP-2022 policy, the project will be eligible for incentives offered by the state government. These typically include financial, infrastructural, and operational support. Specific details of the incentives applicable to this facility were not disclosed in the company’s filing.

Filing and Disclosure

The announcement was made through a stock exchange disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was submitted on April 21, 2025, by Nishu Kansal, Company Secretary and Compliance Officer at Nureca Limited.

Read more: Nifty Pharma Records Steepest Fall Since 2020 – Here’s Why.

Share Price Performance

As of 12:58 PM on April 22, Nureca share price was trading at ₹254.50, down 0.40% for the day, up 12.94% over the past month, and down 10.31% over the past six months.

Conclusion

Nureca’s new project in Punjab has received official clearance and will operate under the provisions of IBDP-2022. The facility will focus on manufacturing wellness equipment and is eligible for policy-linked incentives provided by the state.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.